GMDA

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crispr Therapeutics AG (CRSP – Research Report), Arcutis Biotherapeutics (ARQT – Research Report) and Gamida Cell (GMDA – Research Report) with bullish sentiments. Crispr Therapeutics AG (CRSP) Brookline Capital Markets analyst Leah R. Cann initiated coverage with a Buy rating on Crispr Therapeutics AG today and set a price target of $143.00. The company's shares closed last Monday at $50.09. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-crispr-therapeutics-ag-crsp-arcutis-biotherapeutics-arqt?utm_source=advfn.com&utm_medium=referral